GILEAD SCIENCES, INC. vs Johnson & Johnson, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where GILD and JNJ diverge most: on ev/ebitda, GILD reads 17.4 and JNJ reads 326.4; on revenue growth, GILD reads +3.5% and JNJ reads +8.1%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | GILD | JNJ |
|---|---|---|
| Price | $130.19 | $256.46 |
| Market cap | $163.3B | $625.8B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| P/E | 17.7 | 29.8 |
| P/B | 6.94 | 7.36 |
| P/S | 5.49 | 6.39 |
| EV/EBITDA | 17.4 | 326.4 |
| Revenue growth | +3.5% | +8.1% |
| Gross margin | — | 68.2% |
| Operating margin | 37.2% | — |
| Net margin | 31.0% | 21.5% |
| Return on equity | 39.2% | 24.8% |
| Return on assets | 16.4% | 10.5% |
| Return on invested capital | 17.3% | — |
| FCF yield | 6.3% | 3.5% |
| Dividend yield | 2.4% | 2.0% |
| Debt / equity | 1.00 | 0.58 |
| Current ratio | 1.97 | 1.09 |
| Altman Z (solvency) | 7.23 | 4.95 |
| Piotroski F (quality) | 6 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.